3SOF

QuoteWhat I'm wondering is if the FDA already did approve this in the past, or is this actually the message of approval??

I believe it was approved in the past, that is, this was old news to the market.

Out of 8 holdings on the 3 Stocks on Fire Portfolio, only one shows a loss at this moment, and that's RITA. But, though this stock is showing a loss for me, the technical picture isn't damaged and it is still bullish.

As long as the stock trades above the ascending trendline one knows the trend is bullish and trends usually persist. For tomorrow the ascending trendline will stand at $3.29.

RITA needs to make a white marubozu soon, or I'll fall asleep. So many red and black candles is really annoying. Make that white marubozu or break the support, but please do something, I'm tired !!!

RITA didn't hear me. She doesn't even know I exist. She's the master of her destiny and since I'm not Warren Buffet, I can't do anything to change that. I hope she comes to dance with the bulls, but there are many pretty bears outthere ...

If this girl closes below $3.31 tomorrow I'll have to kiss her goodbye 

David,

I have to say that my love for RITA has cooled down as well but she is still a sexy girl

I didn't fall in love because of the chart's sexy curves. I was enticed by the insider buying and the phenomenal growth and both of these are still intact.



The insiders bought between 2.65 and 3.05. They have an excellent history of insider buying and selling (read they normally make a nice profit!). so I don't think they bought shares for a quick 10% gain!

The market was obviously disappointed that they didn't reach break even in Q2. I do however think they are going to exceed the analysts forecasts in Q3:



I don't see any reasons why the growth would stop in Q3 and the earnings will improve just from the lack of one time costs to the tune of $962 000.

I am therefore going to hold RITA till next quarter is released. I am going to sell immidiately if they do not deliver an earning surprise in that quarter.

From technical, it has strong support at $3.30, then $3.00.

Of course, $2.50 is their absolute support. Whenever the stock touched $2.50, it reversed.

Since 2001, it touched $2.50 five times and all reversed and gained at least 100%.

I will buy it tomorrow at support and exit it if it break down the support.

With improved fundamental, it should not return to year low.

I checked its historical chart and it may run similar to the chart from Aug 2003 to April 2004 where it gained from $2.50 -> $6.75.

Second pull back is $3.50 previous high.

Let us try to buy it tomorrow at its strong support level of $3.30.

News. Two topics.  Might jumpstart some interest today.

http://www.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=&guid=%7B3B61768F%2D50F9%2D4F1A%2D9A50%2DA51260230E66%7D&symb=RITA

RITA Medical Launches New LifeGuard(TM) Vision(TM) Safety Needle; Proprietary ''See-Through'' Feature Designed for Greater Clinician Safety; Low-Profile Safety Needle Designed for Improved Patient Comfort

FREMONT, Calif.--(BUSINESS WIRE)--Aug. 16, 2005--RITA Medical Systems, Inc. (NASDAQ: RITA) today announced the introduction of the LifeGuard Vision safety needle designed to provide safe, secure needle management and low-profile design for improved patient comfort. The LifeGuard Vision safety needle is used by oncology practitioners in combination with RITA Vortex(R) infusion port products and third-party ports in the treatment of patients requiring repeated access of the vascular system or other selected body site, for the delivery of medications, nutritional supplementation, fluids, blood, blood products, and sampling of blood. The new LifeGuard Vision safety needle has been approved by the U.S. Food and Drug Administration (FDA).


Joseph DeVivo, President and CEO of RITA Medical commented, "We believe the LifeGuard Vision safety needle will help us build momentum in this important market while reinforcing the RITA brand in our core oncology customer segment. The LifeGuard Vision is an important addition to our specialty access catheter product line as we execute our strategy to offer a premium, robust and competitively priced infusion product line to our customers."

The LifeGuard Vision expands the Company's integrated product offering to oncology practices worldwide and is the only safety needle product in the industry to use the Company's proprietary clear-bodied low-profile needle guard design. The LifeGuard Vision provides clinicians with both a visible confirmation of needle protection as well as an audible and tactile "click" upon complete needle retraction. The product is designed to improve patient comfort with a low profile design that allows clinicians to apply a flat, secure dressing over the device during use.

The LifeGuard Vision Safety Needle is used to access implanted vascular ports to administer fluids and/or blood products, and/or to withdraw blood. It facilitates safe removal by encapsulating the needle during vascular port de-accessing, helping prevent needle stick injuries.

AND

http://www.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=&guid=%7B28260030%2D3580%2D483F%2DAA56%2DF75338C2D485%7D&symb=RITA

RITA Medical Systems Names Mario Martinez Vice President of Operations, General Manager; Experienced Medical Device Executive to Lead Company's Operations and Serve as General Manager of Manchester, Georgia Facility

FREMONT, Calif.--(BUSINESS WIRE)--Aug. 17, 2005--RITA Medical Systems, Inc. (Nasdaq: RITA), the only publicly traded medical device company focused solely on cancer therapies, today announced the appointment of Mario Martinez, to the position of Vice President of Operations, General Manager. The position is newly created at the company and includes responsibility for company-wide operations including operating personnel, information technology, manufacturing, customer service and distribution. Mr. Martinez will also serve as the General Manager of the Company's Manchester, Georgia facility. Mr. Martinez will report directly to Mr. Joseph DeVivo, President and Chief Executive Officer.


"Mario will be focused on driving improvement in all areas of operations, manufacturing, and customer service throughout RITA. We believe that Mario's track record in medical devices, including radiofrequency ablation, makes him the perfect choice to lead RITA's operations," stated Mr. DeVivo. "With more than 25 years of experience in the medical device industry, we expect that Mario will be a strong leader and a great addition to the RITA management team," he concluded.

Mr. Martinez has held senior management and executive positions with several medical device companies including EP Technologies, a manufacturer of radiofrequency ablation products to treat cardiac arrhythmia, now a division of Boston Scientific (BSX). Prior to joining RITA, Mr. Martinez was a founder, President and CEO of Tecnix, LLC, a technology advisory firm based in Atlanta, GA. Prior to Tecnix Mr. Martinez held corporate officer, senior management and engineering positions with 2C Optics, an ophthalmic research development and commercialization company, with Biofield, a cancer diagnostic company, Cordis, a Johnson & Johnson (JNJ) company, Ohmeda (BOC), Ciba Geigy (Novartis), Coulter Electronics (Beckman Coulter, BEC), and Key Pharmaceuticals (Schering Plough, SGP). Mr. Martinez is a graduate of the Emory University Mini Medical School, the Goldratt Institute, the Covey Leadership Center and Leadership Miami, and received his bachelor's degree from Florida International University. In June of 2005 Mr. Martinez was appointed by Georgia Governor Sonny Perdue as Chairman of the Latino Commission for a New Georgia.

"I am thrilled to be working closely with Joe and his team to make RITA the premier medical device oncology company," Mr. Martinez commented. "I am also very pleased that the Company has selected Georgia as the home for the Company's manufacturing and operations center."

Rita Medical gets FDA OK on resection device - see Reuters

Up 5% in pre-market.

Add to that-

Rita medical announces FDA 510[K] clearance of Habib[TM]4x resection device- PR Newswire
8/18/2005 6;00.34 AM

Quote from: JKN on August 18, 2005, 07:39:41 AM
News. Two topics.  Might jumpstart some interest today.

http://www.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=&guid=%7B3B61768F%2D50F9%2D4F1A%2D9A50%2DA51260230E66%7D&symb=RITA

RITA Medical Launches New LifeGuard(TM) Vision(TM) Safety Needle; Proprietary ''See-Through'' Feature Designed for Greater Clinician Safety; Low-Profile Safety Needle Designed for Improved Patient Comfort

FREMONT, Calif.--(BUSINESS WIRE)--Aug. 16, 2005--RITA Medical Systems, Inc. (NASDAQ: RITA) today announced the introduction of the LifeGuard Vision safety needle designed to provide safe, secure needle management and low-profile design for improved patient comfort. The LifeGuard Vision safety needle is used by oncology practitioners in combination with RITA Vortex(R) infusion port products and third-party ports in the treatment of patients requiring repeated access of the vascular system or other selected body site, for the delivery of medications, nutritional supplementation, fluids, blood, blood products, and sampling of blood. The new LifeGuard Vision safety needle has been approved by the U.S. Food and Drug Administration (FDA).


Joseph DeVivo, President and CEO of RITA Medical commented, "We believe the LifeGuard Vision safety needle will help us build momentum in this important market while reinforcing the RITA brand in our core oncology customer segment. The LifeGuard Vision is an important addition to our specialty access catheter product line as we execute our strategy to offer a premium, robust and competitively priced infusion product line to our customers."

The LifeGuard Vision expands the Company's integrated product offering to oncology practices worldwide and is the only safety needle product in the industry to use the Company's proprietary clear-bodied low-profile needle guard design. The LifeGuard Vision provides clinicians with both a visible confirmation of needle protection as well as an audible and tactile "click" upon complete needle retraction. The product is designed to improve patient comfort with a low profile design that allows clinicians to apply a flat, secure dressing over the device during use.

The LifeGuard Vision Safety Needle is used to access implanted vascular ports to administer fluids and/or blood products, and/or to withdraw blood. It facilitates safe removal by encapsulating the needle during vascular port de-accessing, helping prevent needle stick injuries.

AND

http://www.marketwatch.com/tools/quotes/newsarticle.asp?siteid=mktw&sid=&guid=%7B28260030%2D3580%2D483F%2DAA56%2DF75338C2D485%7D&symb=RITA

RITA Medical Systems Names Mario Martinez Vice President of Operations, General Manager; Experienced Medical Device Executive to Lead Company's Operations and Serve as General Manager of Manchester, Georgia Facility

FREMONT, Calif.--(BUSINESS WIRE)--Aug. 17, 2005--RITA Medical Systems, Inc. (Nasdaq: RITA), the only publicly traded medical device company focused solely on cancer therapies, today announced the appointment of Mario Martinez, to the position of Vice President of Operations, General Manager. The position is newly created at the company and includes responsibility for company-wide operations including operating personnel, information technology, manufacturing, customer service and distribution. Mr. Martinez will also serve as the General Manager of the Company's Manchester, Georgia facility. Mr. Martinez will report directly to Mr. Joseph DeVivo, President and Chief Executive Officer.


"Mario will be focused on driving improvement in all areas of operations, manufacturing, and customer service throughout RITA. We believe that Mario's track record in medical devices, including radiofrequency ablation, makes him the perfect choice to lead RITA's operations," stated Mr. DeVivo. "With more than 25 years of experience in the medical device industry, we expect that Mario will be a strong leader and a great addition to the RITA management team," he concluded.

Mr. Martinez has held senior management and executive positions with several medical device companies including EP Technologies, a manufacturer of radiofrequency ablation products to treat cardiac arrhythmia, now a division of Boston Scientific (BSX). Prior to joining RITA, Mr. Martinez was a founder, President and CEO of Tecnix, LLC, a technology advisory firm based in Atlanta, GA. Prior to Tecnix Mr. Martinez held corporate officer, senior management and engineering positions with 2C Optics, an ophthalmic research development and commercialization company, with Biofield, a cancer diagnostic company, Cordis, a Johnson & Johnson (JNJ) company, Ohmeda (BOC), Ciba Geigy (Novartis), Coulter Electronics (Beckman Coulter, BEC), and Key Pharmaceuticals (Schering Plough, SGP). Mr. Martinez is a graduate of the Emory University Mini Medical School, the Goldratt Institute, the Covey Leadership Center and Leadership Miami, and received his bachelor's degree from Florida International University. In June of 2005 Mr. Martinez was appointed by Georgia Governor Sonny Perdue as Chairman of the Latino Commission for a New Georgia.

"I am thrilled to be working closely with Joe and his team to make RITA the premier medical device oncology company," Mr. Martinez commented. "I am also very pleased that the Company has selected Georgia as the home for the Company's manufacturing and operations center."

the first one about the needle was out yesterday premarket...

Quote from: 1reilly on August 18, 2005, 07:48:32 AM
Add to that-

Rita medical announces FDA 510[K] clearance of Habib[TM]4x resection device- PR Newswire
8/18/2005 6;00.34 AM

this sounds like really good news..

anyone knows what the impact (financily) could be?

The FDA clearance of Habib4X came a bit earlier than I expected (not complaining!). This adds additional 1 million to the revenue for Q3 and Q4 according to RITA's Q2 release:

QuoteThere is upside to our revenue outlook for the full year, which is based on our ability to market the Habib 4X in the United States. We believe the Habib 4X can have an incremental revenue impact in 2005 of up to $1 million depending on the timing of FDA regulatory approval of the device.

Whoops, I grapped the wrong story, meant to post the one about the Habib device.

Thanks nikao...

Looks good in the premarket...

RITA's timing is perfect.. I think she reads this board too..and was afraid to get lonely when we all are leaving her

You go GIRL!

News came to the rescue on RITA. Things like these happen when the stock has attractive fundamentals 

I'll just put the links for the news out today:

RITA Medical Announces FDA 510(K) Clearance of Habib(TM)4x Resection Device
Company Expects to Begin Shipping Device in Mid-September 2005

Michael already did excellent fundamental analysis on RITA, insiders seem to agree with him and the market agrees too. So I'll keep my plan and hold the stock as long as it closes above the ascending trendline (no doubt it has technical validity). Tomorrow the line will stand at $3.32, rising a bit everyday.

I read somewhere the cost of the device is $50 while they are selling it at $1K. So it's all profit.